Related Experiment Video
Updated: Feb 11, 2026

Identification of Growth Inhibition Phenotypes Induced by Expression of Bacterial Type III Effectors in Yeast
Published on: March 30, 2010
Identification of a Small Molecule That Selectively Inhibits ERG-Positive Cancer Cell Growth
Ahmed A Mohamed1, Charles P Xavier1, Gauthaman Sukumar2
1Center for Prostate Disease Research, Department of Surgery, Uniformed Services University of the Health Sciences and the Walter Reed National Military Medical Center, Bethesda, Maryland.
Abstract:
Oncogenic activation of the ETS-related gene (ERG) by recurrent gene fusions (predominantly TMPRSS2-ERG) is one of the most validated and prevalent genomic alterations present in early stages of prostate cancer. In this study, we screened small-molecule libraries for inhibition of ERG protein in TMPRSS2-ERG harboring VCaP prostate cancer cells using an In-Cell Western Assay with the highly specific ERG-MAb (9FY). Among a subset of promising candidates, 1-[2-Thiazolylazo]-2-naphthol (NSC139021, hereafter ERGi-USU) was identified and further characterized. ERGi-USU selectively inhibited growth of ERG-positive cancer cell lines with minimal effect on normal prostate or endothelial cells or ERG-negative tumor cell lines. Combination of ERGi-USU with enzalutamide showed additive effects in inhibiting growth of VCaP cells. A screen of kinases revealed that ERGi-USU directly bound the ribosomal biogenesis regulator atypical kinase RIOK2 and induced ribosomal stress signature. In vivo, ERGi-USU treatment inhibited growth of ERG-positive VCaP tumor xenografts with no apparent toxicity. Structure-activity-based derivatives of ERGi-USU recapitulated the ERG-selective activity of the parental compound. Taken together, ERGi-USU acts as a highly selective inhibitor for the growth of ERG-positive cancer cells and has potential for further development of ERG-targeted therapy of prostate cancer and other malignancies.Significance: A highly selective small-molecule inhibitor of ERG, a critical driver of early stages of prostate cancer, will be imperative for prostate cancer therapy. Cancer Res; 78(13); 3659-71. ©2018 AACR.
Insights
Researchers identified ERGi-USU, a novel small molecule that selectively inhibits the ETS-related gene (ERG) protein. This compound shows promise for treating ERG-positive prostate cancer and other malignancies with minimal toxicity.
Area of Science:
- Oncology
- Molecular Biology
- Drug Discovery
Background:
- The ETS-related gene (ERG) is frequently activated by gene fusions in early prostate cancer.
- Targeting ERG represents a validated therapeutic strategy for ERG-positive malignancies.
Purpose of the Study:
- To identify and characterize novel small-molecule inhibitors of ERG protein.
- To evaluate the therapeutic potential of ERGi-USU in ERG-driven cancers.
Main Methods:
- Screening of small-molecule libraries using In-Cell Western Assay.
- Characterization of ERGi-USU in cancer cell lines and xenograft models.
- Kinase screening to identify direct targets of ERGi-USU.
Main Results:
- ERGi-USU selectively inhibited the growth of ERG-positive cancer cells.
- ERGi-USU demonstrated additive effects when combined with enzalutamide.
- ERGi-USU directly targets RIOK2, inducing ribosomal stress and inhibiting tumor xenograft growth without apparent toxicity.
Conclusions:
- ERGi-USU is a potent and selective inhibitor of ERG.
- ERGi-USU shows significant potential for the development of novel ERG-targeted therapies for prostate cancer and other cancers.
More Related Videos
09:10Synthesis of Masarimycin, a Small Molecule Inhibitor of Gram-Positive Bacterial Growth
Published on: January 7, 2022
10:28Flow Cytometry-based Drug Screening System for the Identification of Small Molecules That Promote Cellular Differentiation of Glioblastoma Stem Cells
Published on: January 10, 2018
Related Concept Videos
Positive Regulator Molecules
Positive Regulator Molecules
Feedback Inhibition
Position-effect Variegation
Chromatin Position Affects Gene Expression
Topologically Associated Domains (TADs)
The 3-dimensional positioning of chromatin in the nucleus influences the...
T Cell Activation and Clonal Selection
Naive T cells that have not yet encountered an antigen express two primary CD...